FDA to disclose advisors' financial ties

The FDA is planning to let some blue sky into its advisory committees. In an attempt to stifle conflicts of interest, the agency wants to tell the public about any advisory committee member's financial ties to the drug industry.

Now, experts who advise the agency on drugs and other products have to disclose these financial relationships. If the FDA chooses to allow the expert onto the committee anyway, it has to announce that it's granted that person a waiver. But details of the financial relationships aren't shared. Last year, a study showed that a quarter of the advisory-committee experts had a financial conflict. Only 1 percent of them were excluded from serving.

- check out the FDA's release
- read the report from the Associated Press

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.